JAK 2 EXON 12 MUTATION DETECTION Test
Components: Price – 1260.0 AED
Sample Condition: 3 mL (2 mL min.) whole blood from 1 Lavender Top (EDTA) tube. Ship refrigerated. DO NOT FREEZE.
Duly filled Genomics Clinical Information Requisition Form (Form 20) is mandatory.
Report Delivery: Sample Mon / Thu by 11 am; Report Wed / Sat
Method: PCR, Fragment Analysis
Test type: Cancer
Doctor: Oncologist
Test Department: MOLECULAR DIAGNOSTICS
Pre Test Information: Duly filled Genomics Clinical Information Requisition Form (Form 20) is mandatory.
Test Details
The JAK2 exon 12 mutation detection test is a laboratory test that is used to detect mutations in the JAK2 gene in exon 12. This test is primarily used to diagnose and monitor certain types of blood disorders, such as polycythemia vera (PV) and other myeloproliferative neoplasms (MPNs).
The JAK2 gene provides instructions for making a protein that plays a crucial role in regulating the production of blood cells. Mutations in the JAK2 gene, particularly in exon 12, can lead to the overproduction of red blood cells, which is a characteristic feature of PV and other MPNs.
The JAK2 exon 12 mutation detection test involves analyzing a blood or bone marrow sample to identify any mutations in exon 12 of the JAK2 gene. This is typically done using a technique called polymerase chain reaction (PCR), which amplifies the DNA in the sample and allows for the detection of specific mutations.
The results of the test can help healthcare providers determine whether a patient has a JAK2 exon 12 mutation, which can aid in the diagnosis and management of PV and other MPNs. It is important to note that this test specifically looks for mutations in exon 12 of the JAK2 gene and may not detect mutations in other regions of the gene.
Overall, the JAK2 exon 12 mutation detection test is a valuable tool in the diagnosis and monitoring of certain blood disorders, providing important information for healthcare providers to develop appropriate treatment plans for their patients.
Test Name | JAK 2 EXON 12 MUTATION DETECTION Test |
---|---|
Components | |
Price | 1260.0 AED |
Sample Condition | 3 mL (2 mL min.) whole blood from 1 Lavender Top (EDTA) tube. Ship refrigerated. DO NOT FREEZE. Duly filled Genomics Clinical Information Requisition Form (Form 20) is mandatory. |
Report Delivery | SampleMon / Thu by 11 am; Report Wed / Sat |
Method | PCR, Fragment Analysis |
Test type | Cancer |
Doctor | Oncologist |
Test Department: | MOLECULAR DIAGNOSTICS |
Pre Test Information | Duly filled Genomics Clinical Information Requisition Form (Form 20) is mandatory. |
Test Details | The JAK2 exon 12 mutation detection test is a laboratory test that is used to detect mutations in the JAK2 gene in exon 12. This test is primarily used to diagnose and monitor certain types of blood disorders, such as polycythemia vera (PV) and other myeloproliferative neoplasms (MPNs). The JAK2 gene provides instructions for making a protein that plays a crucial role in regulating the production of blood cells. Mutations in the JAK2 gene, particularly in exon 12, can lead to the overproduction of red blood cells, which is a characteristic feature of PV and other MPNs. The JAK2 exon 12 mutation detection test involves analyzing a blood or bone marrow sample to identify any mutations in exon 12 of the JAK2 gene. This is typically done using a technique called polymerase chain reaction (PCR), which amplifies the DNA in the sample and allows for the detection of specific mutations. The results of the test can help healthcare providers determine whether a patient has a JAK2 exon 12 mutation, which can aid in the diagnosis and management of PV and other MPNs. It is important to note that this test specifically looks for mutations in exon 12 of the JAK2 gene and may not detect mutations in other regions of the gene. Overall, the JAK2 exon 12 mutation detection test is a valuable tool in the diagnosis and monitoring of certain blood disorders, providing important information for healthcare providers to develop appropriate treatment plans for their patients. |